Skip to Content

'
Patrick M. Lynch, J.D., M.D.

Present Title & Affiliation

N/A

Education & Training

Degree-Granting Education

1983 Creighton University School of Medicine, Omaha, NE, MD, Medicine

Postgraduate Training

7/1986-6/1988 Clinical Fellowship, Gastroenterology, Baylor College of Medicine, Houston, TX
7/1984-6/1986 Clinical Residency, University of Arkansas for Medical Sciences, Little Rock, AR
7/1983-6/1984 Clinical Internship, University of Arkansas for Medical Sciences, Little Rock, AR

Board Certifications

1/1988 Gastroenterology, Board Eligible
1/1986 American Board of Internal Medicine

Experience/Service

Academic Appointments

Associate Professor, Department of Gastroenterology, Hepat,& Nutr, Division of Internal Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1996-8/2009

Institutional Committee Activities

Member, Executive Committee of Prevention Faculty, 1/1997-1/1999
Member, Criteria for Advancement Committee (ad hoc), 1/1995
Member, Quality Assurance Committee, Gastroenterology, 1/1993-1/1999
Member, Program Committee: "Advances in Biology and Therapy of Colorectal Cancer", 1/1993

Professional Memberships

Alpha Omega Alpha Honorary Medical Society
Member, 1/1983-present
American Gastroenterological Association
Member, 1/1992-present
Chairman, Subcommittee on Colorectal Cancer, Clinical Teaching Program (CTP) Committee, 1/1992-1/1998
American Society for Gastrointestinal Endoscopy
member, 1989-present
American Society of Clinical Oncology
Member, Task Force on Cancer Genetics Education, 1/1997-1/2000
Member, 1/1995-1/2000
Member, Subcommittee on Cancer Genetic Testing, 1/1995-1/2000
Cancer Studies Consortium Task Force on Preventive Recommendations
Member, 1/1995-1/2000
Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA)
Council Member, 1/2001-present
President, 1/2000-1/2001
Cooperative Family Registry for Colorectal Cancer Studies
Member, Advisory Committee, 1/1997-present
International Society for Gastrointestinal Hereditary Tumours
Governing Council and Member, 1/2003-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Pande M, Amos CI, Osterwisch DR, Chen J, Lynch PM, Broaddus R, Frazier ML. Genetic variation in genes for the xenobiotic-metabolizing enzymes CYP1A1, EPHX1, GSTM1, GSTT1, and GSTP1 and susceptibility to colorectal cancer in Lynch syndrome. Cancer Epidemiol Biomarkers Prev 17(9):2393-401, 9/2008. PMID: 18768509.
2. Lynch PM. Chemoprevention with special reference to inherited colorectal cancer. Fam Cancer 7(1):59-64, 2008. PMID: 17680350.
3. Lynch PM. Standards of care in diagnosis and testing for hereditary colon cancer. Fam Cancer 7(1):65-72, 2008. PMID: 17701450.
4. Lynch PM. New issues in genetic counseling of hereditary colon cancer. Clin Cancer Res 13(22 Pt 2):6857s-61s, 11/2007. PMID: 18006790.
5. Patel PR, Mansfield PF, Crane CH, Wu TT, Lee JH, Lynch PM, Morris J, Pisters PW, Feig B, Sunder PK, Izzo JG, Ajani JA. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer 110(5):989-95, 9/2007. e-Pub 7/2007. PMID: 17636525.
6. Pande M, Chen J, Amos CI, Lynch PM, Broaddus R, Frazier ML. Influence of methylenetetrahydrofolate reductase gene polymorphisms C677T and A1298C on age-associated risk for colorectal cancer in a caucasian lynch syndrome population. Cancer Epidemiol Biomarkers Prev 16(9):1753-9, 9/2007. PMID: 17855693.
7. Chen J, Sen S, Amos CI, Wei C, Jones JS, Lynch P, Frazier ML. Association between Aurora-A kinase polymorphisms and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Mol Carcinog 46(4):249-256, 1/2007. PMID: 17219423.
8. Ross WA, Alkassab F, Lynch PM, Ayers GD, Ajani J, Lee JH, Bismar M. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. Gastrointest Endosc 65:70-6, 1/2007. PMID: 17185082.
9. Lynch Ht, Lynch JF, Lynch PM, Attard T. Hereditary colorectal cancer syndromes: Molecular genetics, genetic counseling, diagnosis and management. Familial Cancer 7:27-39, 2007.
10. Rosen L, Bilchik A, Beart R, Jr., Benson A III, Chang K, Crompton C, Grothey A, Haller D, Lo C, Lynch P, Nelson H, Stamos M, Turner R, Willert G. New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancer: Summary Statement from 2007 Santa Monica Conference. Clinical Cancer Research 13(22):6853s-56s, 2007.
11. Lynch PM. Prevention of colorectal cancer in high-risk populations: the increasing role for endoscopy and chemoprevention in FAP and HNPCC. Digestion 76(1):68-76, 2007. PMID: 17947820.
12. Lynch P, Delano FA, Schmid-Schonbeing GW. The primary valves in the initial lympatics during inflammation. Lympat Res Biol 5(1):3-10, 2007.
13. Lynch H, Boland CR, Rodriguez-Bigas MA, Amos C, Lynch JF, Lynch P. Who Should Be Sent for Genetic Testing in Hereditary Colorectal Cancer Syndrome? Journal of Clinical Oncology 25(23):3534-3542, 2007.
14. Lynch HT, Lynch PM. Clinical selection of candidates for mutational testing for cancer susceptibility. Oncology(14 Suppl 10):29-34, 12/2006.
15. Glebov OK, Rodriguez LM, Lynch P, Patterson S, Lynch H, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, Denobile J, Soballe P, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 15(7):1382-91, 7/2006. PMID: 16835340.
16. Jones JS, Amos CI, Pande M, Gu X, Chen J, Campos IM, Wei Q, Rodriguez-Bigas M, Lynch PM, Frazier ML. DNMT3b polymorphism and hereditary nonpolyposis colorectal cancer age of onset. Cancer Epidemiol Biomarkers Prev 15:886-91, 5/2006. PMID: 16702365.
17. Lynch PM. Current approaches in familial colorectal cancer: a clinical perspective. J Natl Compr Canc Netw 4(4):421-30, 4/2006. PMID: 16569392.
18. Lynch PM. Does regular use of aspirin reduce the risk of colorectal cancer? Nat Clin Pract Oncol 3(4):186-7, 4/2006. PMID: 16596142.
19. Levin B, Barthel JS, Burt RW, David DS, Ford JM, Giardiello FM, Gruber SB, Halverson AL, Hamilton S, Kohlmann W, Ludwig KA, Lynch PM, Marino C, Martin W Jr, Mayer RJ, Pasche B, Pirruccello SJ, Rajput A, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D, Winawer SJ. Colorectal Cancer Screening Clinical Practice Guidelines. J Natl Compr Canc Netw 4:384-420, 2006.
20. Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcon PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 4:156-76, 2006.
21. Zecevic M, Amos CI, Gu X, Campos IM, Jones JS, Lynch PM, Rodriguez-Bigas MA, Frazier ML. IGF1 gene polymorphism and risk for hereditary nonpolyposis colorectal cancer. J Natl Cancer Inst 98(2):139-43, 2006. PMID: 16418517.
22. Lynch HT, Boland CR, Gong G, Shaw TG, Lynch PM, Fodde R, Lynch JF, de la Chapelle A. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet 14:390-402, 2006.
23. Linder NM, Peterson GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, Lynch P, Burke W, Press N. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296:1507-1517, 2006.
24. Lynch HT, Fusaro RM, Lynch PM. Sebaceous skin lesions as clues to hereditary non-polyposis colorectal cancer. J Invest Dermatol 126:2158-2159, 2006.
25. Wallace MH, Lynch PM. The current status of chemoprevention in FAP. Fam Cancer 5:289-294, 2006.
26. Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R, Hamilton SR, Lynch P, Levin B, Fischer SM, Lippman SM. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res 65(24):11486-92, 12/2005. PMID: 16357157.
27. Jones JS, Gu X, Lynch PM, Rodriguez-Bigas M, Amos CI, Frazier ML. ATM polymorphism and hereditary nonpolyposis colorectal cancer (HNPCC) age of onset (United States). Cancer Causes Control 16(6):749-53, 8/2005. PMID: 16049814.
28. Church J, Berk T, Bonman BM, Guillem J, Lynch C, Lynch P, Rodriguez-Bigas M, Rusin L, Weber T. Collaborative Group of the Americans on Inherited Colorectal Cancer. Dis Colon Rectum 2005 8:1528-34, 8/2005.
29. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen LM, Allen B, Conrad P, Terdiman J, Sun C, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105(3):569-74, 3/2005. PMID: 15738026.
30. Gritz ER, Peterson SK, Vernon SW, Marani SK, Baile WF, Watts BG, Amos CI, Frazier ML, Lynch PM. Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 23(9):1902-10, 3/2005. PMID: 15774782.
31. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23(6):1237-44, 2/2005. PMID: 15718321.
32. Pentz RD, Peterson SK, Watts B, Vernon SW, Lynch PM. Hereditary nonpolyposis colorectal cancer family members' perceptions about the duty to inform and health professionals' role in disseminating genetic information. Genet Test 9:261-268, 1/2005.
33. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, Lynch PM, Rice DC, Roth JA, Ajani JA. Failure patterns correlate with the proportion of residual carcinoma after preoperative Chemoradiotherapy for carcinoma of the esophagus. Cancer 104(7):1349-1355, 2005. PMID: 16130133.
34. Abraham SC, Park SJ, Cruz-Correa M, Houlihan PS, Half EE, Lynch PM, Wu TT. Frequent CpG island methylation in sporadic and syndromic gastric fundic gland polyps. Am J Clin Pathol 122(5):740-6, 11/2004. PMID: 15491970.
35. Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 10(17):5845-9, 9/2004. PMID: 15355915.
36. Broaddus RR, Lynch PM, Lu KH, Luthra R, Michelson SJ. Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome. Mod Pathol 17(8):981-9, 8/2004. PMID: 15143336.
37. Agarwal B, Swisher S, Ajani J, Kelly K, Fanning C, Komaki RR, Putnam JB, Jr, Abu-Hamda E, Molke KL, Walsh GL, Correa AM, Ho L, Liao Z, Lynch PM, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao J, Roth JA. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol 99(7):1258-66, 7/2004. PMID: 15233663.
38. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS, Gunderson LL. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22(14):2774-80, 7/2004. PMID: 15254045.
39. Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB, Jr, Lynch PM, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 100(11):2347-54, 6/2004. PMID: 15160337.
40. Amos CI, Keitheri-Cheteri MB, Sabripour M, Wei C, McGarrity TJ, Seldin MF, Nations L, Lynch PM, Fidder HH, Friedman E, Frazier ML. Genotype-phenotype correlations in Peutz-Jeghers syndrome. J Med Genet 41(5):327-33, 5/2004. PMID: 15121768.
41. Cotton PB, Durkalski VL, Pineau BC, Palesch YY, Mauldin PD, Hoffman B, Vining DJ, Small WC, Affronti J, Rex D, Kopecky KK, Ackerman S, Burdick JS, Brewington C, Turner MA, Zfass A, Wright AR, Iyer RB, Lynch P, Sivak MV, Butler H. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. Jama 291(14):1713-9, 4/2004. PMID: 15082698.
42. Jones JS, Gu X, Campos IM, Lynch PM, Amos CI, Frazier ML. GSTM1 polymorphism does not affect hereditary nonpolyposis colorectal cancer age of onset. Cancer Epidemiol Biomarkers Prev 13(4):676-8, 4/2004. PMID: 15066938.
43. Xiao Z, Luke BT, Izmirlian G, Umar A, Lynch PM, Phillips RK, Patterson S, Conrads TP, Veenstra TD, Greenwald P, Hawk ET, Ali IU. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res 64(8):2904-9, 4/2004. PMID: 15087410.
44. Sinicrope, FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC. Familial Adenomatous Polyposis Study Group. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 1 13((6)):920-927, 2004.
45. Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus 17(1):38-43, 2004. PMID: 15209739.
46. Frazier ML, Xi L, Zong J, Viscofsky N, Rashid A, Wu EF, Lynch PM, Amos CI, Issa JP. Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer. Cancer Res 63(16):4805-8, 8/2003. PMID: 12941799.
47. Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, DeNobile J, Soballe P, Simon R, Wright G, Lynch P, Patterson S, Lynch H, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 12(8):755-62, 8/2003. PMID: 12917207.
48. Lynch HT, Cristofaro G, Rozen P, Vasen H, Lynch P, Mecklin JP, St John J. History of the International Collaborative Group on Hereditary Non Polyposis Colorectal Cancer. Fam Cancer 2(Suppl 1):3-5, 2003. PMID: 14574154.
49. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50(6):857-60, 6/2002. PMID: 12010890.
50. Lynch PM. Screening colonoscopy for family history of colorectal cancer: a growing consensus. Ann Surg Oncol 9(5):425-7, 6/2002. PMID: 12052750.
51. Howe JR, Shellnut J, Wagner B, Ringold JC, Sayed MG, Ahmed AF, Lynch PM, Amos CI, Sistonen P, Aaltonen LA. Common deletion of SMAD4 in juvenile polyposis is a mutational hotspot. Am J Hum Genet 70(5):1357-62, 5/2002. PMID: 11920286.
52. Lynch P. Different familial adenomatous polyposis phenotypes resulting from deletions of the entire APC exon 15. Hum Genet 111:88-95, 2002.
53. Yao JC, Schnirer,, II, Reddy S, Chiang S, Najam A, Yu C, Giacco G, Hess K, Rashid A, Xie K, Lynch P, Ajani JA. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer 5(4):208-12, 2002. PMID: 12491078.
54. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92(2):279-86, 7/2001. PMID: 11466680.
55. Kong S, Wei Q, Amos CI, Lynch PM, Levin B, Zong J, Frazier ML. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst 93(14):1106-8, 7/2001. PMID: 11459873.
56. Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey JN, Lynch P, Ellis LM, Wolff R, Lenzi R, Abbruzzese J, Pazdur R, Hoff PM, Allen P, Brown T, Skibber J. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 24(2):107-12, 4/2001. PMID: 11319280.
57. Lynch PM. COX-2 inhibition in clinical cancer prevention. Oncology (Williston Park) 15(3 Suppl 5):21-6, 3/2001. PMID: 11301836.
58. Frazier ML, O'Donnell FT, Kong S, Gu X, Campos I, Luthra R, Lynch PM, Amos CI. Age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes. Cancer Res 61(4):1269-71, 2/2001. PMID: 11245417.
59. Wu G, Wu W, Hegde M, Fawkner M, Chong B, Love D, Su LK, Lynch P, Snow K, Richards CS. Detection of sequence variations in the adenomatous polyposis coli (APC) gene using denaturing high-performance liquid chromatography. Genet Test 5(4):281-90, 2001. PMID: 11960572.
60. Crane CH, Janjan NA, Abbruzzese JL, Curley S, Vauthey J, Sawaf HB, Dubrow R, Allen P, Ellis LM, Hoff P, Wolff RA, Lenzi R, Brown TD, Lynch P, Cleary K, Rich TA, Skibber J. Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. Int J Radiat Oncol Biol Phys 49(1):107-16, 2001. PMID: 11163503.
61. Komaki R, Janjan NA, Ajani JA, Lynch PM, Fairweather JS, Raijman I, Blumenshein GR, Ho L, Pisters PW, Feig BW, Walsh GL, Pazdur R. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncology (Williston Park) 14(12 Suppl 14):34-7, 12/2000. PMID: 11200147.
62. Frazier ML, Su LK, Amos CI, Lynch PM. Current applications of genetic technology in predisposition testing and microsatellite instability assays. J Clin Oncol 18(21 Suppl):70S-4S, 11/2000. PMID: 11060331.
63. Su LK, Barnes CJ, Yao W, Qi Y, Lynch PM, Steinbach G. Inactivation of germline mutant APC alleles by attenuated somatic mutations: a molecular genetic mechanism for attenuated familial adenomatous polyposis. Am J Hum Genet 67(3):582-90, 9/2000. PMID: 10924409.
64. Janjan NA, Crane CN, Feig BW, Cleary K, Dubrow R, Curley SA, Ellis LM, Vauthey J, Lenzi R, Lynch P, Wolff R, Brown T, Pazdur R, Abbruzzese J, Hoff PM, Allen P, Brown B, Skibber J. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 47(3):713-8, 6/2000. PMID: 10837955.
65. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342(26):1946-52, 6/2000. PMID: 10874062.
66. Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, Buzdar AU, Hortobagyi GN. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 355(9200):281-3, 1/2000. PMID: 10675076.
67. Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 60(2):249-52, 1/2000. PMID: 10667569.
68. Lynch PMand Et Al. 77. ASCO Subcommittee on Genetic Testing for Cancer Susceptibility: Statement of the American Society of Clinical Oncology: Genetic Testing for Cancer Susceptibility. JCO, 2000.
69. Su LK, Steinbach G, Sawyer JC, Hindi M, Ward PA, Lynch PM. Genomic rearrangements of the APC tumor-suppressor gene in familial adenomatous polyposis. Hum Genet 106(1):101-7, 2000. PMID: 10982189.
70. Agarwal, B, Swisher S, Ajani J, Kelly K, Fanning C, Komaki RR, Putnam JB, Ho L, Abu-Hamda E, Molke KL, Walsh GL, Correa AM, Zhongxing L, Lynch PM, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao J, Roth JA. Persistent malignant lymphadenopathy after pre-operative chemoradiation for esophageal carcinoma identifies patients with poor post-operative survival. (submitted), 2000.
71. Lynch, PM. The hMSH2 and hMCH1 Genes in Hereditary Nonpolyposis Colorectal Cancer. Surgical Oncology Clinics of North America. Submitted.

Invited Articles
1. Lynch HT, Lynch JF, Lynch PM. Toward a consensus in molecular diagnosis of hereditary nonpolyposis colorectal cancer (Lynch syndrome). J National Cancer Institute(99(4)):261-3, 2/2007.
2. Lynch PM. Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory? Gastroenterology 131(6):2003-5, 12/2006.
3. Lynch PM. Medicolegal aspects of endoscopic screening and genetic testing in hereditary colon cancer symdromes. Techniques in Gastrointestinal Endoscopy:133-39, 2006.
4. Half EE, Lynch PM. Mutated DNA in the stool - does it have a role in colorectal cancer screening? Nat Clin Pract Gastroenterol Hepatol 3:594-5, 2006.
5. Lynch HT, Lynch PM. Molecular screening for the Lynch syndrome-better than family history? N Engl Med 352(18):1920-22, 5/2005.
6. Abu-Hamda EM, Hattab EM, Lynch PM. Small bowel tumors. Curr Gastroenterol Rep 5:386-93, 10/2003. PMID: 12959719.

Editorials
1. Lynch HT, Lynch PM. Molecular screening for the Lynch syndrome - better than family history? N Engl J Med 352:1920-22, 2005.
2. Lynch PM. Screening colonoscopy for family history of colorectal cancer: a growing consensus. Ann Surg Oncol 9:425-27, 2002.
3. Lynch PM. If aggressive surveillance in hereditary nonpolyposis colorectal cancer (HNPCC) is now state-of-the-art, are there any challenges left? Gastroenterology 118:969-977, 2000.
Other Articles
1. Lynch PM. Does regular use of aspirin reduce the risk of colorecatal cancer. Nat Clin Pract Oncol 3:186-7, 2006.

Abstracts
1. Sinicrope F, Joshi N, Gerner E, Morlan W, Lynch PM, Kirsch I, Broaddus R. Effects of α-Difluoromethylornithine (DFMO) on Histopathology, Mucosal Polyamines, and Gene Expression Profiles in Patients with Dysplastic Barrett's Epithelium. Gastroenterology:A-635, 2008.
2. Lynch PM, Saraiya DS. Non-surgical management of Attenuated Familial Adenomatous Polyposis: Results of a long-term surveillance program. Gastroenterology(A-162), 2008.
3. Lu KH, Watts BG, Soliman PT, Boyd-Rogers SG, Daniels MS, Broaddus RR, Lynch PM, Peterson SK. A prospective pilot study of combined colon and endometrial cancer screening in women with HNPCC. Familial Cancer 4:104-5, 2005.
4. Lynch P, Burke C, Hawk E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Benfield R, Half E, Miller D, Ayes GD. Colonoscopy in a phase I safety trial of celecoxib in cihldren with FAP. Familial Cancer 4:57, 2005.
5. Burke CA, Lynch PM, Phillips R, Hawk E, Church J, Hasson H, Miller D, Burke S. Considerations for maximizing randomization in chemoprevention trials in FAP. Familial Cancer 4:76-77, 2005.
6. Burke C, Hawk E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Benfield R, Half E, Miller D, Ayers GD, Lynch PM. Design and primary safety outcome in a phase I trial of celecoxib in children with FAP. Familial Cancer 4:77-8, 2005.
7. Lynch P, Burke C, Hawk E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Half E, Ayers D. Efficacy and safety in a phase I safety trial of celecoxib in children with FAP. AGA, 2005.
8. Peterson SK, Askins MA, Watts BG, Burke CA, Hasson H, Chuch J, Schover LR, Hawk E, Lynch PM. Family resiliency and functioning among families with APC-postive children. Familial Cancer 4:49-50, 2005.
9. Peterson SK, Watts BG, McGivern B, Burke S, Latchford A, Phillips R, Burke C, Church J, Hasson H, Lynch PM. FAP-affected adults" responses to reported cardiovascular risks associated with celecoxib. CGA, 2005.
10. Peterson, SK, Lynch PM, et al. Psychosocial evaluation of children and parents involved in a phase I study of celecoxib in children with FAP. CGA 2004 (submitted)., 2005.
11. Peterson, SK, Lynch PM, Burke C, Church J, Hasson H, Hawk E. Psychosocial evaluation of children and parents involved in a phase I study of celecoxib in children with FAP. CGA (submitted)., 2004.
12. Half E, Su L-K, Lunagomez S, Steinbach G, Patterson S, Phillips RK, Latchford A, Hawk E, Lynch PM. Response to celecoxib in familial adenomatous polyposis (FAP) does not depend on genotype or adenoma burden. DDW, 2004.
13. Peterson, SK, Watts BG, Lynch PM, Vernon SW, Kapoor S, Gritz ER. Family characteristics associated with nonreferral of relatives for HNPCC genetic counseling and testing. Am J Human Genetics 71:239, 2002.
14. Amos, CI, Frazier ML, Lynch PM, McGarrity TJ. Genetic studies of Peutz-Jeghers syndrome. Am J Med Genet 67:S83, 2000.
15. Barnes, CJ, Steinbach G, Hittelman WN, Lynch PM, Terry NHA, Su L-K. Isolation, confocal microscopy, and molecular analysis of intact colon epithelial structures from pancancerous lesions of individuals with an inherited risk for colorectal cancer. American Association for Cancer Research, 3/1999.
16. Lynch, PM, Steinbach G, Hittelman W, Terry N, Frazier M, Abbruzzese J, Gordon G, Hawk E, Kirsch I, Lynch H. A phase II chemoprevention trial in HNPCC utilizing a selective cyclooxygenase 2 inhibitor: protocol description and progress to date. J Gastroenterol Hepatol 14((8)):A59, 1999.
17. Steinbach, G, Lynch PM, Phillips R, Wallace M, Hawk E, Gordan G, Sherman J, Wakabayashi N, Saunders B, Shen Y, Godio L, Patterson S, Abbruzzese J, Jester S, King K, Zimmerman S, Levin B. Effect of celecoxib on colorectal polyps in patients with familial adenomatous polyposis (FAP). . Am J Gastroenterol, 1999.
18. Amos, CI, Newsome M, Cleary KR, McGarrity TJ, Seldin MF, Lynch PM, Anderson JP, Frazier ML. Genetic epidemiology of Peutz-Jeghers syndrome. Am Assoc Cancer Res 40:465, 1999.
19. Amos CI, Lynch PM, Cleary KR, McGarrity TJ, Seldin MF, Anderson JP, Frazier ML. Genetic epidemiology of Peutz-Jeghers syndrome. J Gastroenterol Hepatol 14:A78, 1999.
20. Brown T, Janjan NA, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey N, Lynch PP, Ellis LM, Wolff R. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Intl J Radit Oncol Biol Phys 45:A2122, 1999.
21. Frazier, ML, Amos CI, Cleary KR, Gritz E, Watts B, Lynch P, Luthra R. Mutations in hereditary nonpolyposis colon cancer (HNPCC) cases. J Gastroenterol Hepatol 14((8)):A60, 1999.
22. Janjan, NA, Crane CH, Feig BW, Cleary K, Dubrow R, Curley S, Ellis LM, Vauthey N, Lenzi R, Lynch P. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal canc. Intl J Radiat Oncol Biol Phys 45((3) 177):a60, 1999.
23. Sinicrope, FA, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y, Frazier ML. Reduced expression of cyclooxygenase-2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. J Gastroenterol Hepatol 14((8)):A59, 1999.
24. Ajani, JA, Mansfield PF, Janjan N, Pisters P, Lynch P, Raijman I, Pazdur R, Goswitz M, Feig B, Hargraves K, Myerson R, Gunderson L. Preoperative chemoradiation therapy (CTRT) in patients with potentially resectable gastric carcinoma: a multi-institutional pilot. ASCO, 1998.
25. Janjan, NA, Skibber J, Feig BW, Cleary K, Dubrow R, Goswitz M, Ellis L, Curley S, Lynch P, Wolff R, Abbruzzese J. Preoperative Concomitant Boost Radiotherapy with Continuous Infusion 5-Fluorouracil for Locally Advanced Rectal Cancer: Preliminary Analysis of Surgical and Pathologic Outcomes. Proceedings of the 40th Annual ASTRO Meeting, 1998.
26. Nesbitt, J, Ajani JA, Komaki R, Walsh G, Putnam J, Swisher S, Pisterse P, Lynch P, Raijman I, Pazdur R, Delclos M, Martin F, Roth J. Preoperative taxol-based chemotherapy followed by chemoradiation therapy in patients with potentially resectable esophageal carcinoma. ASCO, 1998.

Book Chapters
1. Lynch PM. Colorectal cancer: screening and primary prevention. In: Gastrointestinal Cancer. Springer Science+Business Media, Inc: New York, pp 85-103, 2005.
2. Swisher, SG, Komaki R, Lynch PM, Ajani JA. Esophageal carcinoma. (Submitted)., 2000.
3. Lynch PM. How can I help with research? . In: Colorectal Cancer Can Run in the Family.(Submitted). Medcom Asia Pacific, 2000.
4. Wallace, M, Lynch PM. Primary prevention of colorectal cancer (diet and chemoprevention). In: Frontiers in Surgery. (Submitted), 2000.
5. Wallace, M, Lynch PM. The current status of chemoprevention in FAP. In: Familial Cancer on FAP (Submitted), 2000.
6. Lynch PM. The role of inheritance in the diagnosis and management of gastrointestinal malignancies. In: The Principles and Practice of Gastrointestinal Oncology.(In press). Oxford University Press, 2000.

Books (edited and written)
1. Gastrointestinal Cancer. Springer Science+Business Media, Inc, 2005.

Letters to the Editor
1. Lynch P. If aggressive surveillance in hereditary nonpolyposis colorectal cancer is now state of the art, are there any challenges left? Gastroenterology 118(5):969-71, 5/2000. PMID: 10784597.
2. Lynch, HT, Lynch PM, Harris RE. Proximal colon cancer in familial carcinoma of the colon exclusive of familial polyposis coli. Lancet:1306-1307., 2000.

Manuals, Teaching Aids, Other Teaching Publications
1. Weber, BL, Olopade OI, Blackwood MA, Cummings S, Eng C, Garber JE, Lynch PM, Offit K, Rodriguez-Bigas MA, Tomlinson G, Tranin AS. ONCOSEP: Genetics, Oncology Self-Education Program. Kendall/Hunt Publishing Company, 2000.

Last updated: 9/22/2009